ORCHARD THERAPEUTICS PLC Net Income
ORCHARD THERAPEUTICS PLC reported Net Income of -$35.32 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2023-11-13
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for the quarter ending 2023-09-30 was -$35.32M.
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for the quarter ending 2023-06-30 was -$12.31M.
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for the quarter ending 2023-03-31 was -$17.41M.
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for the quarter ending 2022-12-31 was -$7.88M.
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for fiscal 2022 was -$150.66M.
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for fiscal 2021 was -$144.58M.
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for fiscal 2020 was -$151.98M.
- ORCHARD THERAPEUTICS PLC net income (loss) attributable to parent for fiscal 2019 was -$163.42M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$35.32M 10-Q · filed 2023-11-13 | -$47.63M derived: sum of 2 quarters · filed 2023-11-13 | -$65.04M 10-Q · filed 2023-11-13 | -$72.92M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | -$12.31M 10-Q · filed 2023-11-13 | -$29.72M 10-Q · filed 2023-08-10 | -$37.60M derived: sum of 3 quarters · filed 2023-11-13 | -$85.17M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | -$17.41M 10-Q · filed 2023-11-13 | -$25.30M derived: sum of 2 quarters · filed 2023-11-13 | -$72.86M derived: sum of 3 quarters · filed 2023-11-13 | -$123.78M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | -$7.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$55.45M derived: sum of 2 quarters · filed 2023-11-13 | -$106.36M derived: sum of 3 quarters · filed 2023-11-13 | -$150.66M 10-K · filed 2023-03-14 |
| 2022-09-30 | -$47.56M 10-Q · filed 2023-11-13 | -$98.48M derived: sum of 2 quarters · filed 2023-11-13 | -$142.78M 10-Q · filed 2023-11-13 | -$179.13M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$50.92M 10-Q · filed 2023-11-13 | -$95.21M 10-Q · filed 2023-08-10 | -$131.56M derived: sum of 3 quarters · filed 2023-11-13 | -$168.00M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-03-31 | -$44.30M 10-Q · filed 2023-11-13 | -$80.64M derived: sum of 2 quarters · filed 2023-11-13 | -$117.09M derived: sum of 3 quarters · filed 2023-11-13 | -$153.70M derived: sum of 4 quarters · filed 2023-11-13 |
| 2021-12-31 | -$36.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$72.79M derived: sum of 2 quarters · filed 2023-03-14 | -$109.40M derived: sum of 3 quarters · filed 2023-03-14 | -$144.58M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$36.45M 10-Q · filed 2022-11-14 | -$73.05M derived: sum of 2 quarters · filed 2022-11-14 | -$108.24M 10-Q · filed 2022-11-14 | -$141.86M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$36.61M 10-Q · filed 2022-11-14 | -$71.79M 10-Q · filed 2022-08-04 | -$105.41M derived: sum of 3 quarters · filed 2022-11-14 | -$125.70M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | -$35.18M 10-Q · filed 2022-11-14 | -$68.80M derived: sum of 2 quarters · filed 2022-11-14 | -$89.09M derived: sum of 3 quarters · filed 2022-11-14 | -$136.59M derived: sum of 4 quarters · filed 2022-11-14 |
| 2020-12-31 | -$33.62M 10-K · filed 2021-03-02 | -$53.91M derived: sum of 2 quarters · filed 2021-11-04 | -$101.41M derived: sum of 3 quarters · filed 2021-11-04 | -$151.98M 10-K · filed 2022-03-30 |
| 2020-09-30 | -$20.29M 10-Q · filed 2021-11-04 | -$67.79M derived: sum of 2 quarters · filed 2021-11-04 | -$118.36M 10-Q · filed 2021-11-04 | -$163.78M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$47.50M 10-Q · filed 2021-11-04 | -$98.07M 10-Q · filed 2021-08-04 | -$143.49M derived: sum of 3 quarters · filed 2021-11-04 | -$180.22M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-03-31 | -$50.57M 10-Q · filed 2021-11-04 | -$95.98M derived: sum of 2 quarters · filed 2021-11-04 | -$132.72M derived: sum of 3 quarters · filed 2021-11-04 | -$183.25M derived: sum of 4 quarters · filed 2021-11-04 |
| 2019-12-31 | -$45.42M 10-K · filed 2021-03-02 | -$82.15M derived: sum of 2 quarters · filed 2021-03-02 | -$132.68M derived: sum of 3 quarters · filed 2021-03-02 | -$163.42M 10-K · filed 2021-03-02 |
| 2019-09-30 | -$36.74M 10-K · filed 2021-03-02 | -$87.27M derived: sum of 2 quarters · filed 2021-03-02 | -$118.01M 10-Q · filed 2020-11-03 | -$143.07M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | -$50.53M 10-K · filed 2021-03-02 | -$81.27M 10-Q · filed 2020-08-06 | -$106.33M derived: sum of 3 quarters · filed 2021-03-02 | -$140.22M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | -$30.74M 10-K · filed 2021-03-02 | -$55.80M derived: sum of 2 quarters · filed 2021-03-02 | -$89.69M derived: sum of 3 quarters · filed 2021-03-02 | -$245.92M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | -$25.06M 10-K · filed 2020-02-27 | -$58.95M derived: sum of 2 quarters · filed 2020-02-27 | -$215.18M derived: sum of 3 quarters · filed 2020-02-27 | -$230.50M 10-K · filed 2020-02-27 |
| 2018-09-30 | -$33.89M 10-K · filed 2020-02-27 | -$190.12M derived: sum of 2 quarters · filed 2020-02-27 | -$205.43M 6-K · filed 2019-11-07 | |
| 2018-06-30 | -$156.23M 10-K · filed 2020-02-27 | -$171.54M 6-K · filed 2019-08-08 | ||
| 2018-03-31 | -$15.31M 10-K · filed 2020-02-27 | |||
| 2017-12-31 | -$39.74M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | -$19.09M 20-F · filed 2019-03-22 |